NKARTA INC (NKTX)

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 167 full-time employees. The company went IPO on 2020-07-10. The firm is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. The Company’s product candidates include NKX101 and NKX019, which are in ongoing Phase I clinical trials. NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy donors. The company is engineered with a chimeric antigen receptor (CAR) targeting NKG2D ligands on tumor cells. NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. The company is engineered with a humanized CD19-directed CAR for enhanced tumor cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support.

Company Info

NKARTA INC

1150 Veterans Boulevard

South San Francisco CALIFORNIA 94080

P: 19254071049

CEO: Paul J. Hastings

Employees: 167

Website: https://www.nkartatx.com/